Hims & Hers Expands Access To Wegovy And Ozempic Through Novo Nordisk Partnership And Offering Lower-Cost Treatment Options

Hims & Hers Health, Inc. (NYSE: HIMS) has partnered with Novo Nordisk to expand access to a range of FDA-approved GLP-1 medications, including Wegovy, the only FDA-approved weight loss pill. Eligible customers can now access these treatments at lower prices, with options for various doses and delivery methods, starting at $149 a month. This initiative positions Hims & Hers as the largest global consumer health platform for affordable access to approved medications, enabling customers to potentially lose up to 20% of their body weight.